Medicina
Departamento
Universitat de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat de Barcelona (1.154)
2025
2024
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
The Lancet, Vol. 404, Núm. 10459, pp. 1227-1239
-
A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
Cancers, Vol. 16, Núm. 9
-
Acne keloidalis nuchae: An international multicentric review of 79 patients
Journal of the European Academy of Dermatology and Venereology
-
Analysis of the reasons for requesting HIV serology in the emergency department other than those defined in the targeted screening strategy of the “Urgències VIHgila” program and its potential inclusion in a future consensus document
Enfermedades Infecciosas y Microbiologia Clinica
-
Apolipoprotein E-ϵ2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study
Circulation Research, Vol. 134, Núm. 4, pp. 411-424
-
Association between subclinical atherosclerosis burden and unrecognized myocardial infarction detected by cardiac magnetic resonance in middle-aged low-risk adults
European Heart Journal Cardiovascular Imaging, Vol. 25, Núm. 7, pp. 968-975
-
Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population
Journal of Endocrinological Investigation, Vol. 47, Núm. 6, pp. 1405-1418
-
Association of intravenous digoxin use in acute heart failure with rapid atrial fibrillation and short-term mortality according to patient age, renal function, and serum potassium
European Journal of Emergency Medicine, Vol. 31, Núm. 5, pp. 347-355
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy
npj Breast Cancer, Vol. 10, Núm. 1
-
Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry
Pediatric Rheumatology , Vol. 22, Núm. 1
-
Clinical features and prognosis of prosthetic valve endocarditis due to Staphylococcus aureus
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 10, pp. 1989-2000
-
Clinical nutrition in primary care: ESPEN position paper
Clinical Nutrition
-
Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism
Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246
-
Combining loop with thiazide diuretics in patients discharged home after a heart failure decompensation: Association with 30-day outcomes
European Journal of Internal Medicine, Vol. 127, pp. 126-133
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Neurologia, Vol. 39, Núm. 2, pp. 196-208